EyeCon 2026 Banner

News
Media
Conferences
Events
Publications
CME
Partners
Subscribe
Resources

Opinion|Videos|June 30, 2024

Overview of the Port Delivery System with Ranibizumab

Author(s)Margaret A. Chang, MD, MS

Margaret Chang, MD, examines the difficulties of frequent anti-VEGF injections and outlines the key aspects of the port delivery system (PDS) for ranibizumab administration.

Episodes in this series

This series features 1 KOL.

EP. 1 Surgical Considerations and Patient Selection for PDS With Ranibizumab

This series features 1 KOL.

EP. 2 Overview of the Port Delivery System with Ranibizumab

This series features 1 KOL.

EP. 3 Steps for implantation and refill of PDS with ranibizumab

Why is sustained delivery of anti-VEGF necessary, and what challenges arise from frequent anti-VEGF injections?
Can you provide an overview of the port delivery system with ranibizumab?
1. How does the device function?
2. How is the device implanted?
3. How is the device refilled?
What are the benefits of using the PDS with ranibizumab, and which patients are ideal candidates for this delivery method?

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Content

(Image credit: AdobeStock/Zofia) Expanding the ICRS toolkit: Keraring for high regular astigmatism

Expanding the ICRS toolkit: Keraring for high regular astigmatism

ByOphthalmology Times Staff Reports

June 19th 2026

(Image credit: AdobeStock/Nichaphat)

Where eye care leaders go to grow: OWL's annual summit lands in Nashville July 30–31, 2026

ByOphthalmology Times Staff

June 18th 2026

(Image credit: Ophthalmology Times) IOLs: What Every Surgeon Needs to Know | Ep. 2: Enhanced monofocal IOLs

IOLs: What Every Surgeon Needs to Know | Ep. 2: Enhanced monofocal IOLs

ByDouglas D. Koch, MD,Karolinne Maia Rocha, MD, PhD

June 18th 2026

FDA accepts Outlook Therapeutics' resubmitted BLA for ONS-5010 (LYTENAVA)

ByMartin David Harp

June 17th 2026

4 experts are featured in this series

Durability With Aflibercept 8 mg in Retinal Vascular Diseases

ByJonathan Jonisch, MD,Anton Kolomeyer, MD PhD,David A. Eichenbaum, MD, FASRS,Esther Lee Kim, MD

June 15th 2026

Latest CME

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; John Hovanesian, MD, FACS

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD

Retina Updates in Montréal

In-Person + Virtual Event

Retina Updates in Montréal

July 16-17, 2026

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Solange Peters, MD, PhD; Benjamin P. Levy, MD; Tony S.K. Mok, MD, BMSc, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO; Maurice Pérol, MD

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Mark Schaeffer, OD, FAAO; Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO, FAAOMS; Selina R. McGee, OD, FAAO

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

SriniVas Sadda, MD, FARVO; Nathan Steinle, MD

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Mark R. Barakat, MD, FASRS; David Eichenbaum, MD, FASRS

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Dante Pieramici, MD, FASRS; Dean Eliott, MD; Robin A. Vora, MD; Charles C. Wykoff, MD, PhD, FASRS

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

David Almeida, MD, PhD, MBA; Margaret A. Chang, MD, MS; Arshad M. Khanani, MD, MA, FASRS; Jessica Randolph, MD

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

Dilsher Dhoot, MD, FASRS; Jordana G. Fein, MD, MS; Deep Parikh, MD; Xiao-Yi (Ellie) Zhou, MD

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

Ramiro Maldonado, MD; Rebecca Nelson, MS, CGC; Robert A. Sisk, MD, FACS, FASRS

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Basil Williams, MD; Maura Di Nicola, MD

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

John Kitchens, MD; Michael W. Stewart, MD

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

FDA accepts Outlook Therapeutics' resubmitted BLA for ONS-5010 (LYTENAVA)

Tinlarebant NDA submission completed for Stargardt disease type 1, targeting first approved therapy

Expanding the ICRS toolkit: Keraring for high regular astigmatism

Study finds mixed real and synthetic eye images enhance ocular AI performance

IOLs: What Every Surgeon Needs to Know | Ep. 2: Enhanced monofocal IOLs